Use of omalizumab is associated with improvement of pruritic skin disorders induced by immune checkpoint inhibitors: A retrospective cohort from the European Task Force of Dermatology for Cancer patients

Francesc Alamón‐Reig, Xavier Bosch‐Amate, Priscila Giavedoni, Vasiliki Nikolaou, Cristina Mangas, Zoé Apalla, Ander Mayor Ibarguren, Chrysa Oikonomou, Michela Starace, V. Sibaud, Cristina Carrera